http://www.medicalnewstoday.com/articles/234478.php
At the 47th Annual Meeting of the European Association for the Study of Diabetes Novartis announced results of a study that revealed Galvus® (vildagliptin) has a similar safety profile to placebo when added to anti-diabetic therapy in patients with type 2 diabetes (T2DM) and moderate or severe renal impairment. The Novartis-sponsored vildagliptin study also revealed that vildagliptin achieved significant improvements in glycemic control when added to current therapy.
At the 47th Annual Meeting of the European Association for the Study of Diabetes Novartis announced results of a study that revealed Galvus® (vildagliptin) has a similar safety profile to placebo when added to anti-diabetic therapy in patients with type 2 diabetes (T2DM) and moderate or severe renal impairment. The Novartis-sponsored vildagliptin study also revealed that vildagliptin achieved significant improvements in glycemic control when added to current therapy.